Immunoconjugate: Difference between revisions
CSV import |
CSV import Tags: mobile edit mobile web edit |
||
| Line 31: | Line 31: | ||
[[Category:Biological Therapy]] | [[Category:Biological Therapy]] | ||
{{stub}} | {{stub}} | ||
{{No image}} | |||
Revision as of 02:10, 11 February 2025
Immunoconjugate is a type of biological therapy that combines a monoclonal antibody with a cytotoxic drug or a radioactive particle. The monoclonal antibody binds to specific proteins or antigens on cancer cells, delivering the cytotoxic drug or radioactive particle directly to the cancer, which may help decrease damage to healthy cells. Immunoconjugates are used in the treatment of certain types of cancer.
Overview
Monoclonal antibodies are laboratory-produced molecules that can locate and bind to cancer cells wherever they are in the body. They can be used alone, or they can be used to deliver drugs, toxins, or radioactive material directly to tumor cells.
An immunoconjugate is a complex of an antibody (or an antibody fragment) linked to a second molecule, which might be a chemotherapeutic agent, a toxin, or a radioactive compound. The antibody binds to specific antigens on the surface of the cell, delivering the second molecule to the cell.
Types of Immunoconjugates
There are several types of immunoconjugates, including Antibody-drug conjugates (ADCs), Radioimmunotherapy (RIT) agents, and Immunotoxins.
Antibody-Drug Conjugates
Antibody-drug conjugates (ADCs) are monoclonal antibodies (mAbs) attached to biologically active drugs. By combining the unique targeting of mAbs with the cancer-killing ability of cytotoxic drugs, ADCs allow sensitive discrimination between healthy and diseased tissue.
Radioimmunotherapy
Radioimmunotherapy (RIT) involves the use of radioactively conjugated murine antibodies against cellular antigens. RIT allows targeted delivery of radiation to the cancer cells.
Immunotoxins
Immunotoxins are a group of protein-based therapeutics composed of a targeting moiety linked to a toxin. The targeting moiety is usually a monoclonal antibody that recognizes and binds to specific cell surface antigens.
Clinical Applications
Immunoconjugates have been used in the treatment of various types of cancers, including breast cancer, lymphoma, and leukemia. They have shown promise in clinical trials, with some immunoconjugates being approved for use by the Food and Drug Administration (FDA).
